Patients had to have evidence of CD19+ B cell acute lymphoblastic leukemia with >5% blasts in bone marrow or a minimal residual disease of 1 × 10−3 cells as assessed by flow cytometry or quantitative polymerase chain reaction. Here, CD19 is linked to acute lymphoblastic leukemia.